242 related articles for article (PubMed ID: 18706728)
1. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
Zuur CL; Simis YJ; Verkaik RS; Schornagel JH; Balm AJ; Dreschler WA; Rasch CR
Radiother Oncol; 2008 Oct; 89(1):38-43. PubMed ID: 18706728
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
3. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
4. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of low-dose cisplatin-based chemo-irradiation in assessing hearing loss for locally advanced head and neck cancer.
Liao XB; Yan SX
Radiother Oncol; 2009 Feb; 90(2):282, author reply 282-3. PubMed ID: 19042049
[No Abstract] [Full Text] [Related]
6. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
[TBL] [Abstract][Full Text] [Related]
7. Decreased hearing after combined modality therapy for head and neck cancer.
Pearson SE; Meyer AC; Adams GL; Ondrey FG
Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors.
Zuur CL; Simis YJ; Lamers EA; Hart AA; Dreschler WA; Balm AJ; Rasch CR
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):490-6. PubMed ID: 19135315
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients.
Pan CC; Eisbruch A; Lee JS; Snorrason RM; Ten Haken RK; Kileny PR
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1393-402. PubMed ID: 15817342
[TBL] [Abstract][Full Text] [Related]
10. Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma.
Hoebers FJ; Heemsbergen W; Balm AJ; van Zanten M; Schornagel JH; Rasch CR
Radiother Oncol; 2007 Oct; 85(1):42-7. PubMed ID: 17445927
[TBL] [Abstract][Full Text] [Related]
11. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study.
Low WK; Toh ST; Wee J; Fook-Chong SM; Wang DY
J Clin Oncol; 2006 Apr; 24(12):1904-9. PubMed ID: 16622266
[TBL] [Abstract][Full Text] [Related]
12. Postoperative reduced dose of cisplatin concomitant with radiation therapy in high- risk head and neck squamous cell carcinoma.
Franchin G; Minatel E; Politi D; Gobitti C; Talamini R; Vaccher E; Savignano MG; Trovo M; Sulfaro S; Barzan L
Cancer; 2009 Jun; 115(11):2464-71. PubMed ID: 19280588
[TBL] [Abstract][Full Text] [Related]
13. A new grading system for ototoxicity in adults.
Theunissen EA; Dreschler WA; Latenstein MN; Rasch CR; van der Baan S; de Boer JP; Balm AJ; Zuur CL
Ann Otol Rhinol Laryngol; 2014 Oct; 123(10):711-8. PubMed ID: 24820112
[TBL] [Abstract][Full Text] [Related]
14. High-dose cisplatin treatment: hearing loss and plasma concentrations.
Laurell G; Jungnelius U
Laryngoscope; 1990 Jul; 100(7):724-34. PubMed ID: 2362532
[TBL] [Abstract][Full Text] [Related]
15. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
Chan SH; Ng WT; Kam KL; Lee MC; Choi CW; Yau TK; Lee AW; Chow SK
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1335-42. PubMed ID: 18922648
[TBL] [Abstract][Full Text] [Related]
16. Influence of low-dose daily cisplatin on the distant metastasis-free survival of patients with locally advanced nonmetastatic head and neck cancer treated with radiation therapy.
Jeremić B; Milicić B
Radiother Oncol; 2008 May; 87(2):201-3. PubMed ID: 18207598
[TBL] [Abstract][Full Text] [Related]
17. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
18. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.
Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer.
Ishikawa E; Sugimoto H; Hatano M; Nakanishi Y; Tsuji A; Endo K; Kondo S; Wakisaka N; Murono S; Ito M; Yoshizaki T
Acta Otolaryngol; 2015 Sep; 135(9):919-24. PubMed ID: 25861690
[TBL] [Abstract][Full Text] [Related]
20. Long-term hearing loss after chemoradiation in patients with head and neck cancer.
Theunissen EA; Zuur CL; Bosma SC; Lopez-Yurda M; Hauptmann M; van der Baan S; de Boer JP; van der Molen L; Rasch CR; Dreschler WA; Balm AJ
Laryngoscope; 2014 Dec; 124(12):2720-5. PubMed ID: 24964759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
